Estrogen, hormonal replacement therapy and cardiovascular disease

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 2, 2011, Pages 133-138

  Yang, Xiao Ping ^a   Reckelhoff, Jane F ^b  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular disease; estrogen; hormonal replacement therapy

Indexed keywords

C REACTIVE PROTEIN; CONJUGATED ESTROGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BETA RHYTHM; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG DOSE COMPARISON; DRUG MEGADOSE; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; GENE EXPRESSION; HEART AFTERLOAD; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; HYSTERECTOMY; INCIDENCE; LOW DRUG DOSE; NONHUMAN; OVARIECTOMY; OVARY INSUFFICIENCY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; QUALITY OF LIFE; RISK REDUCTION; SECONDARY PREVENTION; SEX DIFFERENCE; THROMBOEMBOLISM; TREATMENT DURATION;

AGED; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEX CHARACTERISTICS;

EID: 79952037809     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283431921     Document Type: Article

References (67)

1. Bittner V. Menopause, age, and cardiovascular risk: a complex relationship. J Am Coll Cardiol 2009; 54:2374-2375.
2. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old debate. Hypertension 2008; 51:952-959. (Pubitemid 351398967)
3. Kim ES, Menon V. Status of women in cardiovascular clinical trials. Arterioscler Thromb Vasc Biol 2009; 29:279-283.
4. Reckelhoff JF, Maric C. Sex and gender differences in cardiovascular-renal physiology and pathophysiology. Steroids 2010; 75:745-746.
5. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133:933-941. (Pubitemid 32003509)
6. Rosano GM, Vitale C, FiniM. Cardiovascular aspects of menopausal hormone replacement therapy. Climacteric 2009; 12 (Suppl 1):41-46.
7. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523-534. (Pubitemid 36951364)
8. Hulley S, Grady D, Bush T, et al., for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280:605-613. (Pubitemid 28502636)
9. Hulley S, Furberg C, Barrett-Connor E, et al., for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II). J Am Med Assoc 2002; 288:58-66.
10. Hodis HN. Assessing benefits and risks of hormone therapy in 2008: new evidence, especially with regard to the heart. Cleve Clin J Med 2008; 75 (Suppl 4):S3-S12.
11. Schnatz PF. Hormonal therapy: does it increase or decrease cardiovascular risk? Obstet Gynecol Surv 2006; 61:673-681. (Pubitemid 44450570)
12. Haines CJ, Farrell E. Menopause management: a cardiovascular risk-based approach. Climacteric 2010; 13:328-339.
13. Harman SM. Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEEPS. Gend Med 2006; 3:254-269. (Pubitemid 46923558)
14. Barton M, Meyer MR. Postmenopausal hypertension: mechanisms and therapy. Hypertension 2009; 54:11-18.
15. Kim JK, Alley D, Seeman T, et al. Recent changes in cardiovascular risk factors among women and men. J Womens Health (Larchmt) 2006; 15:734-746. (Pubitemid 44349851)
16. Rosano GM, Vitale C, Marazzi G, Volterrani M. Menopause and cardiovascular disease: the evidence. Climacteric 2007; 10 (Suppl 1):19-24.
17. Wake R, Yoshiyama M. Gender differences in ischemic heart disease. Recent Pat Cardiovasc Drug Discov 2009; 4:234-240.
18. Silbiger S, Neugarten J. Gender and human chronic renal disease. Gend Med 2008; 5 (Suppl A):S3-S10. (Pubitemid 351455227)
19. Anderson RD, Pepine CJ. Gender differences in the treatment for acute myocardial infarction: bias or biology? Circulation 2007; 115:823-826. (Pubitemid 46294721)
20. Matthews KA, Crawford SL, Chae CU, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 2009; 54:2366-2373.
21. Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses' Health Study. Obstet Gynecol 2009; 113:1027-1037.
22. Bairey Merz CN, Johnson BD, Sharaf BL, et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol 2003; 41:413-419. (Pubitemid 36164495)
23. Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009; 16:15-23.
24. Wang F, Keimig T, He Q, et al. Augmented healing process in female mice with acute myocardial infarction. Gend Med 2007; 4:230-247. (Pubitemid 350082738)
25. Dent MR, Tappia PS, Dhalla NS. Gender differences in apoptotic signaling in heart failure due to volume overload. Apoptosis 2010; 15:499-510.
26. Lagranha CJ, Deschamps A, Aponte A, et al. Sex differences in the phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and cardioprotection in females. Circ Res 2010; 106:1681-1691.
27. Javeshghani D, Schiffrin EL, Sairam MR, Touyz RM. Potentiation of vascular oxidative stress and nitric oxide-mediated endothelial dysfunction by high-fat diet in a mouse model of estrogen deficiency and hyperandrogenemia. J Am Soc Hypertens 2009; 3:295-305.
28. Lew R, Komesaroff P, Williams M, et al. Endogenous estrogens influence endothelial function in young men. Circ Res 2003; 93:1127-1133. (Pubitemid 37485045)
29. Kimura M, Sudhir K, Jones M, et al. Impaired acetylcholine-induced release of nitric oxide in the aorta of male aromatase-knockout mice. Regulation of nitric oxide production by endogenous sex hormones in males. Circ Res 2003; 93:1267-1271. (Pubitemid 37543067)
30. Gardner JD, Murray DB, Voloshenyuk TG, et al. Estrogen attenuates chronic volume overload induced structural and functional remodeling in male rat hearts. Am J Physiol Heart Circ Physiol 2010; 298:H497-H504.
31. Cavasin MA, Tao ZY, Yu AL, Yang X-P. Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function. Am J Physiol Heart Circ Physiol 2006; 290:H2043-H2050.
32. Xing D, Nozell S, Chen YF, et al. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol 2009; 29:289-295.
33. Babiker FA, De Windt LJ, van Eickels M, et al. Estrogenic hormone action in the heart: regulatory network and function. Cardiovasc Res 2002; 53:709-719. (Pubitemid 34175263)
34. Barkhem T, Nilsson S, Gustafsson JA. Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J Pharmacogenom 2004; 4:19-28. (Pubitemid 38325702)
35. Ruehlmann DO, Mann GE. Rapid nongenomic vasodilator actions of oestrogens and sex steroids. Curr Med Chem 2000; 7:533-541. (Pubitemid 30396427)
36. Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol 2009; 308:32-38.
37. Deschamps AM, Murphy E. Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol 2009; 297:H1806-H1813.
38. Zhang QG, Raz L, Wang R, et al. Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation. J Neurosci 2009; 29:13823-13836.
39. Lin J, Steenbergen C, Murphy E, Sun J. Estrogen receptor-beta activation results in S-nitrosylation of proteins involved in cardioprotection. Circulation 2009; 120:245-254.
40. Reckelhoff JF. Cardiovascular disease, estrogen deficiency, and inflammatory cytokines. Hypertension 2006; 48:372-373. (Pubitemid 44253728)
41. Donaldson C, Eder S, Baker C, et al. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation. Circ Res 2009; 104:265-275.
42. Wang F, He Q, Sun Y, et al. Female adult mouse cardiomyocytes are protected against oxidative stress. Hypertension 2010; 55:1172-1178.
43. Liu CJ, Lo JF, Kuo CH, et al. Akt mediates 17beta-estradiol and/or estrogen receptor-alpha inhibition of LPS-induced tumor necresis factor-alpha expression and myocardial cell apoptosis by suppressing the JNK1/2-NFkappaB pathway. J Cell Mol Med 2009; 13:3655-3667.
44. Erwin GS, Crisostomo PR, Wang Y, et al. Estradiol-treated mesenchymal stem cells improve myocardial recovery after ischemia. J Surg Res 2009; 152:319-324.
45. Baruscotti I, Barchiesi F, Jackson EK, et al. Estradiol stimulates capillary formation by human endothelial progenitor cells: role of estrogen receptoralpha/beta, heme oxygenase 1, and tyrosine kinase. Hypertension 2010; 56:397-404.
46. Bolego C, Rossoni G, Fadini GP, et al. Selective estrogen receptor-alpha agonist provides widespread heart and vascular protection with enhanced endothelial progenitor cell mobilization in the absence of uterotrophic action. FASEB J 2010; 24:2262-2272.
47. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336:1769-1775.
48. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronaryartery calcification. N Engl J Med 2007; 356:2591-2602.
49. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297:1465-1477. (Pubitemid 46556472)
50. Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab 2001; 86:41-47. (Pubitemid 32109773)
51. Nuedling S, Kahlert S, Loebbert K, et al. Differential effects of 17beta-estradiol on mitogen-activated protein kinase pathways in rat cardiomyocytes. FEBS Lett 1999; 454:271-276. (Pubitemid 29304614)
52. Yasui T, Maegawa M, Tomita J, et al. Changes in serum cytokine concentrations during the menopausal transition. Maturitas 2007; 56:396-403. (Pubitemid 46401105)
53. Georgiadou P, Sbarouni E. Effect of hormone replacement therapy on inflammatory biomarkers. Adv Clin Chem 2009; 47:59-93.
54. Oztas E, Kurtay G. Effects of raloxifene on serum macrophage colonystimulating factor and interleukin-18 levels in postmenopausal women younger than 60 years. Menopause 2010; 17:1188-1193.
55. Karim R, Stanczyk FZ, Hodis HN, et al. Associations between markers of inflammation and physiological and pharmacological levels of circulating sex hormones in postmenopausal women. Menopause 2010; 17:785-790.
56. Kamada M, Irahara M, Maegawa M, et al. Postmenopausal changes in serum cytokine levels and hormone replacement therapy. Am J Obstet Gynecol 2001; 184:309-314. (Pubitemid 32206977)
57. Alexandersen P, Tankó LB, Bagger YZ, et al. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric 2006; 9:108-118.
58. Klaiber EL, Broverman DM, Vogel W, et al. Relationships of serum estradiol levels, menopausal duration, and mood during hormonal replacement therapy. Psychoneuroendocrinology 1997; 22:549-558. (Pubitemid 27505114)
59. Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 1997; 157:2609-2615. (Pubitemid 27519981)
60. Villa P, Suriano R, Ricciardi L, et al. Low-dose estrogen and drospirenone combination: effects on glycoinsulinemic metabolism and other cardiovascular risk factors in healthy postmenopausal women. Fertil Steril 2010 [Epub ahead of print].
61. Appt SE, Clarkson TB, Lees CJ, Anthony MS. Low dose estrogens inhibit coronary artery atherosclerosis in postmenopausal monkeys. Maturitas 2006; 55:187-194. (Pubitemid 44307489)
62. Zhan E, Keimig T, Xu J, et al. Dose-dependent cardiac effect of oestrogen replacement in mice postmyocardial infarction. Exp Physiol 2008; 93:982-993. (Pubitemid 352000276)
63. Meng X, Dai X, Liao T-D, et al. Dose-dependent toxic effects of high-dose estrogen on renal and cardiac injury in surgically postmenopausal mice. Life Sci 2010 [Epub ahead of print].
64. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001; 104:1773-1778. (Pubitemid 32963341)
65. Adams MR, Register TC, Golden DL, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:217-221. (Pubitemid 27057346)
66. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1712. (Pubitemid 38489892)
67. Miller VM, Black DM, Brinton EA, et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009; 2:228-239.